Biogen Unusual Options Activity
Portfolio Pulse from Benzinga Insights
Unusual options activity has been observed for Biogen (NASDAQ:BIIB), with a large position indicating a bullish stance. The sentiment among these big-money traders is split evenly between bullish and bearish. The options activity suggests a target price range of $200 to $350 for Biogen over the last three months. Current price of BIIB is $276.65, up 0.71%. RBC Capital and Morgan Stanley maintain their positive ratings on Biogen with price targets of $341 and $355 respectively, while Needham and HC Wainwright & Co. have downgraded their actions to Buy with price targets of $321 and $325 respectively.
July 21, 2023 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Unusual options activity indicates a bullish stance on Biogen. The target price range is $200-$350. Current price is $276.65, up 0.71%. Analysts have mixed ratings with price targets ranging from $321 to $355.
The unusual options activity, which is typically a sign of significant investor interest, suggests a bullish stance on Biogen. This, combined with the current upward trend in the stock's price and the positive ratings from some analysts, indicates a potential short-term positive impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100